Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Replagal
Active Ingredient: Agalsidase alfa 1mg/mL
Dosage Form: Concentrate for infusion
New Zealand Sponsor: Health Consulting Group Limited
Manufacturer: Chesapeake Biological Laboratories Inc, Baltimore, Maryland, United States of America
Note: This consent is valid for two years from 18 October 2003.
Dated this 24th day of November 2003.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the
6th day of July 2001).